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Background: To report results obtained by combining risk sharing tools with post-adoption surveillance
mechanisms in order to control quality of care and implement a value-based reimbursement scheme for Neuro-
reflexotherapy (NRT), a non-pharmacological treatment proven effective for neck pain (NP), thoracic pain (TP) and
low back pain (LBP).
Methods: Pre-post prospective cohort study in routine clinical practice, carried out in primary care centers in the
Spanish National Health Service in the Balearic Islands (Ib-Salut). Eight-hundred and seventy-one subacute and
chronic NP, TP and LBP patients treated in Ib-Salut, who underwent NRT during 2011. A shared risk contract (SRC)
was developed, where payments for NRT were linked to results on patients’ clinical evolution, reduction in
medication and proportion of patients undergoing spinal surgery. Main outcome measures were local pain (NP, TP
or LBP), referred pain, LBP-related disability and NP-related disability, measured using previously validated
instruments at referral and 3 months later, use of medication assessed at referral and discharge, and rates of spinal
surgery prescription after undergoing NRT.
Results: Median improvements at discharge corresponded to 57.1% of baseline value for local pain, 75.0% for
referred pain, 53.8% for LBP-related disability and 45.0% for NP-related disability. Patients taking medication at
discharge represented 29.0% of those taking it at referral. The proportion of patients in whom spinal surgery was
prescribed after undergoing NRT was 0%. These results were consistent with those from previous randomised
controlled trials (RCTs) and studies in routine practice, and complied with the standards set in the SRC.
Conclusions: It is feasible and effective to enhance post adoption surveillance methods with risk sharing tools to
improve quality control and support value-based reimbursement decisions for NRT. The feasibility of generalising
this approach to other settings and to other non-pharmacological treatments should be explored.Background
Clinical use of health technologies depends on regula-
tory frameworks which vary across countries. Neverthe-
less, the inappropriate use of both pharmacologic and
non-pharmacologic procedures is widespread all over
the world, leading to patients being unnecessarily ex-
posed to potentially harmful procedures and risks, and
to superfluous health costs [1-12].
The objective of shared risk contracts (SRCs) is that
payers and providers share the risks deriving from the* Correspondence: carlos.campillo@ibsalut.es
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distribution, and reproduction in any mediumuncertainties associated with using a given health tech-
nology in routine practice. To this end, SRCs link pay-
ments to providers to whether results in practice reach
pre-established goals. Providers may include health care
providers or, more commonly, providers of products
(e.g., the industry). The pre-established goals can be
defined by levels of usage of a given technology, appro-
priateness of use, and/or clinical outcomes [13-18]. For
instance, following a SRC payments for a new drug can
be partially or totally reduced if clinical outcomes in
routine practice do not reach the cut-off point pre-
viously established in the SRC.
Typically, SRCs have been developed as a pragmatic
way of ensuring coverage for new drugs, usually highlyBioMed Central Ltd. This is an Open Access article distributed under the terms of
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a) existing treatments have not shown to be effective,
b) the evidence on the effectiveness and cost/effectiveness
of the new drugs is either lacking or of low quality, and
c) conducting high quality randomised controlled trials
(RCTs) within a reasonable timeframe is unfeasible. Exam-
ples include conditions with a relatively low incidence or
for which long follow-up periods are necessary for results
to be clinically meaningful [19-21].
In these cases, SRCs allow the health system to pro-
vide treatments which are potentially effective or more
cost-effective than existing alternatives, while: a) gather-
ing data to assess whether the corresponding investment
actually leads to expected outcomes (i.e., “coverage with
evidence development” schemes), b) providing informa-
tion for value-based pricing, c) limiting potential wastage
of payers’ resources, by sharing costs with providers in the
event that the technology does not reach expected out-
comes, and d) strengthening post adoption surveillance.
When pharmacological or non-pharmacological tech-
nologies are implemented in routine practice, application
conditions often vary from those used in RCTs. These
differences may include training standards, indication
criteria (such as “off label” use and other forms of treat-
ment extension effects), and variations in compliance.
As a result, outcomes (including adverse events) in cli-
nical practice can deviate from those in previous RCTs.
Non-specific neck (NP), thoracic pain (TP) and low
back pain (LBP) represent a major clinical, social and
economic burden in industrialised countries [16,22-28].
In routine practice, many treatments are used for
these conditions, although very few are supported by
solid evidence on efficacy, effectiveness, safety and
cost/effectiveness [29-31].
Neuro-reflexotherapy (NRT) is one of the few LBP
treatments supported by high quality evidence [32-35].
It involves temporary (up to 90 days) subcutaneous im-
plantation of surgical material on specific trigger points
[32-35]. The intervention is unrelated to acupuncture
and is designed to deactivate the neurons involved in the
mechanisms which prolong pain, neurogenic inflamma-
tion, and muscle dysfunction and contracture [20-23]. A
more detailed description of the procedure and the
mechanisms explaining its effect, have been published
elsewhere [33]. The evidence available, including the
corresponding Cochrane review, shows that NRT is safe,
more effective than a sham procedure (i.e., implanting
the same number of surgical devices ≤ 5 mm around the
specific trigger points), and that its use in routine practice
significantly increases the effectiveness and cost/effective-
ness of treatment for subacute and chronic LBP in Spain,
and specifically within the Spanish National Health Service
[32-35]. All the evidence-based clinical guidelines which
have reviewed the quality of the evidence on NRT, haverated it as “high” [29,30,36-39] In fact, NRT is the only
non-pharmacological therapy for LBP for which the net
benefit is considered to be “substantial” by the evidence
review supporting the US evidence-based clinical guidelines
for LBP [39]. Moreover, all the guidelines covering the
geographical settings where the procedure was available
have recommended its use in clinical practice [36-38].
The Spanish National Health Service (SNHS) provides
free health care to every resident in Spain. The SNHS is
managed at the regional level and fully financed by
taxes, although regional governments can implement
local taxes or copayments to provide additional funding.
Decisions on coverage of non-pharmacological technolo-
gies can be made at the regional or national level.
In 2004, NRT was implemented in routine practice of
the SNHS in the Balearic Islands (Ib-Salut) for treating
subacute and chronic patients with non-specific NP, TP
and LBP, in the same applications conditions and under
the same post-adoption surveillance methods in which it
had been previously assessed and test-piloted [32-35,40-43].
The latter were designed in such a way that they do not
interfere with routine practice; clinicians routinely gather
all relevant data using validated instruments (e.g., pain se-
verity, disability, etc.), and introduce them in a software
package specifically designed for that purpose [40-43].
The implementation of NRT was based on a fee-
for-service; the Ib-Salut paid providers a fixed amount
for each patient referred for NRT who underwent the
procedure, and a different amount for each patient who
was referred but did not receive NRT (e.g., when pa-
tients did not comply with indication criteria or refused
to sign the informed consent). However, in 2010, the
Ib-Salut and providers agreed to enhance post-adoption
surveillance methods by using risk sharing tools in order
to improve quality of care and to support value-based
reimbursement decisions, starting January 1st, 2011. The
objective of this study was to describe these tools and
their results one year after their implementation.Methods
Study population
In accordance with the referral protocol used in previous
studies (Figure 1) [34,40,41], primary care physicians in
the Ib-Salut referred patients with NP, TP and LBP in
whom pain severity was ≥ 3 points on a 10-point visual
analogue scale (VAS) [44], and lasted ≥ 14 days despite
medication and other treatments, to certified NRT
Units. These indication criteria include patients with
failed back surgery. Exclusion criteria were suffering
neurogenic claudication caused by lumbar spinal sten-
osis, cervical mielopathy or showing criteria for urgent
referral to surgery, such as signs suggesting cauda equina
syndrome (e.g., progressive motor weakness in the legs,
NoYes
Common neck or back pain 
Avoid bed rest/
NSAIDs and/or analgesics and/or muscle relaxants (   14days) 
PersistenceResolved
¿Red flags? (1)
Symptomatic spinal stenosis, cervical mielopathy
or criteria for urgent referral to surgery? (2) 










Figure 1 Referral protocol for NRT intervention [34,40,41].
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level) [22,34,40,41].
Patients with “red flags” suggesting that pain might be
caused by fractures or systematic diseases (such as fever
or unexplained weight loss), could be referred to NRT
only once these conditions had been discarded (Figure 1)
[22,29,30,34,40,41].
All patients undergoing NRT following referral from
Ib-Salut during 2011, and discharged before December
31st, 2011, were included in this study. Patients in whom
adverse events required early extraction of the surgical
material, were identified and excluded from the analyses.Shared risk tools
Following the clauses established in the contract, the pro-
vider invoiced the Ib-Salut 48.57 € for each patient referred
for NRT when the procedure was not performed, and
615.28 € for each NRT intervention. These prices match
those which the Ib-Salut is invoiced for in routine practice.
They were based on the costs associated with NRT in the
RCT which showed this technology to be cost/effective
[33], and have been adjusted for inflation thereafter.
Fixed payments represented 50% of the amount in-
voiced. Variable payments corresponded to the remaining
50%, payable only if results reached the standards defined
in the contract.The variable amount broke down as follows: reaching
the standards for clinical evolution implied payment of
50% of the variable amount; reaching the standards on
the reduction of use of drugs, 30%, and reaching the
standards on rates of spinal surgery, 20%. For instance, if
results did not meet any of the standards, only 50% of
the invoice (the fixed amount) would be paid; if only the
standards on pain and disability were met, only 75% of
the invoice (the fixed amount plus 50% of the variable
amount) would be paid.
The Ib-Salut defined three sets of standards; clinical
standards for patients’ clinical evolution; standards for
the reduction of medication intake; and standards for
the proportion of patients in whom spinal surgery was
prescribed after undergoing NRT.
Clinical standards focused on the most important clin-
ical outcomes for patients with NP, TP or LBP: local pain
(NP, TP or LBP), referred pain, and disability [45]. The
standards for each of these variables was established by
the person designated by the Ib-Salut for this task (CC-A),
in collaboration with the first author of the studies which
had identified the cut-off point for clinical relevance for
these variables in Spanish LBP and NP patients (FMK).
This cut-off point corresponds to 30% of baseline score of
the corresponding variable (local pain, referred pain or
disability), and matches the cut-off established in other
settings [46-49]. Therefore, these standards were
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charge for each one of these variables was ≥ 30% of
baseline score [46-49].
Standards for reduction in medication and for the pro-
portion of spinal surgery among NRT patients, were
established in three phases. Firstly, the Ib-Salut defined
the ideal standards which, if met, would generate savings
above the cost of NRT. Subsequently, the person desig-
nated by the Ib-Salut for developing this SRC (CC-A), In
collaboration with the first author of the RCTs on NRT
(FMK), verified that these standards were realistic, based
on the effect size reported for NRT in: these RCTs,
previous studies conducted in routine practice, the
Cochrane systematic review, and the evidence-based
clinical guidelines [29,32-35,39-43,50]. Finally, since the
reported effect size was equal or above the ideal stan-
dards defined by the Ib-Salut, they were accepted by the
provider and incorporated into the contract. Previous
studies had shown that adverse events from NRT were
minor (essentially, transient skin itching or limited skin
infection) [32-35,40-43]. Therefore, the contract did not
include standards for adverse events. Nevertheless, the
number of patients in whom adverse events required the
extraction of the surgical material, was documented.
Standards for the use of medication focused on pa-
tients’ intake of non-steroidal anti-inflammatory drugs
(NSAIDs), steroids, non-opioid analgesic, codeine, other
opioids, anti-epileptic drugs, and muscle relaxants. Only
use for NP, TP or LB was considered. The Ib-Salut
established these standards as either: a) for each type of
drug, the number of patients using it at discharge was ≤
80% of those using it at baseline, or b) the number of
patients using any of these drugs at discharge was ≤ 80%
of those who did so at baseline.
Decompressive spinal surgery has proven effective for
patients in whom conservative treatment fails to signifi-
cantly improve radicular pain caused by disk herniation
within 6 weeks, or caused by spinal stenosis within 3–6
months [45,51-56]. Although the effectiveness of spinal
fusion for LBP patients without radicular pain remains
controversial [30], it is still considered when conserva-
tive treatments fail for ≥ 2 years [29]. These types of
patients, are often referred to NRT as the “last resource”
to avoid surgery [41,43,57]. Therefore, the Ib-Salut
established that standards for the proportion of spinal
surgery among NRT patients would be met if surgery,
for the reason for which patients had been referred for
NRT, was prescribed to ≤ 20% of the subjects who
underwent the procedure.
Standards were assessed when patients were discharged,
3 months after having undergone the NRT treatment.
Reaching the standards for each of the clinical out-
comes (local pain, referred pain, NP-related disability
and LBP-related disability) implied payment of 12.5%of the variable amount. Disability was not taken into
account among TP patients because validated instru-
ments to measure TP-related disability do not exist.
Reaching the standards for reduction of medication
intake implied payment of 30% of the variable amount,
and reaching the standards for the proportion of NRT
patients in whom spinal surgery was subsequently
prescribed implied payment of 20% of the variable
amount.
Intervention
Following the application conditions in which NRT had
proven effective, safe, and cost-effective [40,51,57], spe-
cialists at the NRT units assessed indication criteria. Pa-
tients complying with indication criteria were presented
written informed consents for undergoing NRT and for
allowing the use of their data for this study. Units in
which the interventions were performed, and physicians
who performed them, had been certified following
specialised professional standards [58]. According to the
Spanish law, this study did not need to be submitted to
an Institutional Review Board.
In the event of experiencing adverse events (e.g.,
itching or skin infection), patients were instructed to
contact the specialised unit or their primary care centre
[32,34,35,40,41]. Cases in which adverse events led to
early extraction of the material, were identified. In the
remaining patients, twelve weeks after the intervention
was performed the surgical material was extracted and
indication criteria for repeating the NRT intervention
were assessed. These criteria are: [34,41] having im-
proved ≥ 2 VAS points after the first intervention, pain
severity still ≥ 3 VAS points, and having patient’s written
consent for repeating it. Patients not meeting these
criteria were discharged.
Outcome assessment
The outcome assessment was based on previously
validated post-adoption surveillance mechanisms which
are used in routine clinical practice [40,41]. Primary care
physicians assessed patients’ clinical condition. Referral
to the certified NRT Unit was determined by them using
a standardised protocol (Figure 1) [40,41].
On patient’s first visit the following data were gath-
ered: gender, age (date of birth); reason for referral (NP,
TP or LBP); time elapsed since first diagnosis (days);
duration of the current pain episode (days); and date of
referral for NRT.
On the first and all subsequent visits to the primary
care centre and the certified NRT Unit, the following
data were gathered: severity of local pain (LP) and re-
ferred pain (RP), disability, employment status (working,
receiving financial compensation for LBP, TP or NP, or
passive –student, housewife, unemployed, etc.-); pregnancy;
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ment in litigation; diagnostic tests undergone (X-Rays,
MRI, electromyogram, etc.); test results (e.g., imaging find-
ings), and therapeutic procedures prescribed (including
drug treatment and spinal surgery).
Data on pain and disability were provided by patients.
They rated these variables on their own and without
assistance or interference from clinicians or auxiliary
personnel. Separate 10-cm VAS were used for local pain
(NP, TP or LBP) and referred pain (RP) [44]. The Span-
ish version of the Roland-Morris Questionnaire (RMQ)
was used to score LBP-related disability [59]. The Neck
Disability Index (NDI) was used to assess NP-related
disability [60]. From best to worst, value ranges for these
instruments are 0–10 for VAS, 0–24 for RMQ and
0–100 for NDI [44,48,59].
Data were introduced into a database by auxiliary staff
independent from the clinicians. Clinicians had access to
these data (since they are useful for clinical decisions –e.g.,
repeating the NRT intervention-), but could not alter
them.
Every month, patients who were discharged were iden-
tified, and data on their clinical status, drug use and
prescription of surgery during the follow-up period were
transferred to the team in charge of analysing results.Analysis
Analysis of results was performed by a team who had no
contact with the clinicians involved in performing the
interventions or with the administrative staff in charge
of payments at the Ib-Salut.
Absolute and relative frequencies were calculated for
categorical variables. Values for continuous variables
were described through their median and interquartile
range (IQR).
According to the available evidence, data on duration of
the current pain episode were categorised as subacute
(14–90 days), and chronic pain (> 90 days) [61,62]. There
is no evidence for categorising the time elapsed since first
diagnosis. Data on this variable were categorised as ≤ 1
year, 1–5 years, 5–10 years, and > 10 years.
Analyses were limited to data from patients who had
undergone NRT, excluding those who had been referred
for the procedure but did not undergo it (e.g., those not
complying with indication criteria), and those in whom
adverse events required early extraction of the surgical
material implanted. The total number of these patients
was registered.
At the design phase of this study, it was decided that
the number of patients with missing values for data rele-
vant to assess whether the standards had been met (e.g.,
patients not answering the VAS, RMQ or NDI question-
naires) would be registered and, if ≥ 10%, a sensitivityanalysis would be performed assuming that all missing
data had been failures.
In order to assess whether standards were met, the
following procedures were used. The median and IQR of
VAS scores for local pain (NP, TP or LBP) at baseline
and at the end of the follow-up period were calculated.
The same procedure was repeated for the VAS scores for
referred pain, the RMQ scores for LBP-related disability
(including only data from patients referred to NRT for
LBP) and NDI scores for NP-related disability (including
only data from patients referred to NRT for NP). The
number of patients who were using NSAID, steroids,
non-opioid analgesic, codeine, other opioids, anti-epileptic
drugs, and muscle relaxants when referred for NRT and at
discharge, was determined. The number of patients using
any kind of drug at baseline and discharge, was also identi-
fied. Finally, patients in whom spinal surgery had been
prescribed for the reason why they had previously been
referred to NRT, were identified.
The number of patients with missing data (e.g., pa-
tients who did not answer the instruments to assess pain
and disability at baseline and at discharge) was also
identified.
Since outcome assessment occurred 3 months after
performing the NRT intervention, variable payments
related were delayed for at least that period. Therefore,
in order to prevent delays in payments which might have
compromised feasibility of the contract, invoicing
and preliminary assessment of results were performed
monthly from April onwards, based on the data from
patients discharged during the previous month. Ana-
lyses comprising all data of patients treated during
2011 were repeated in April 2012, when data and out-
comes for all NRT interventions performed during that
year became available.
Each month, the analysts assessed whether the stan-
dards had been met and listed the names of the patients
discharged, grouping those who complied and did not
comply with each of the standards, separately. The
administrative staff of the Ib-Salut had full access to the
database containing all patients’ data, checked that data
on patients’ use of medication and prescription of sur-
gery coincided with those from the Ib-Salut’s database,
double-checked that lists of patients complying and not
complying with the standards was correct, and verified
that the global assessment of whether each standard was
met, was correct. It had been planned that if discrepan-
cies or doubts arose, providers, analysts and the admin-
istrative staff of the Ib-Salut would meet to discuss
them. All data were transferred to the person desig-
nated by the Ib-Salut to monitor results from NRT
(CC), who authorised the administrative of the Ib-Salut
to pay the amount corresponding to the standards
which had been met.
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nisms, data were routinely captured in daily practice
[40,41]. Therefore, analyses only involved assessing
whether results matched the standards established in
the contract, which required less than 30 minutes per
month. The team responsible for data analysts was
employed full-time and paid a fixed monthly salary.
Hence, the cost of conducting the analyses was consid-
ered negligible and was not measured.
Results
During 2011, 909 patients referred by the Ib-Salut for
NP (244 patients), TP (61) and LBP (604), underwent
NRT and were discharged before the 31st of December
2011. All patients complying with indication criteria for
NRT, signed their informed consents.
Adverse events required early extraction of the surgi-
cal material in only 38 (4.2%) patients. All adverse events
consisted of skin reactions; in 7 patients, they were trig-
gered by a previously unknown allergy to metal, and in
31 cases they consisted of recurrent or persistent local
skin infection, despite topical treatment with an anti-
biotic cream. None of the cases required systemic treat-
ment and the reaction disappeared after the surgical
devices were extracted in all cases.
Therefore, 871 patients were included in this study.
Their characteristics are shown in Table 1.
Some patients did not respond to the questionnaires
on baseline severity of local pain (one patient), LBP-
related disability (two patients) and NP-related disability
(six patients). At discharge, some patients left some
questionnaires unanswered; the VAS for local pain (one
patient), the VAS for referred pain (three patients), the
questionnaire assessing LBP-related disability (RMQ)
(three patients), and the one assessing NP-related dis-
ability (NDI) (16 patients). Some patients left some
questionnaires unanswered at baseline and discharge.
The numbers for VAS for local pain, VAS for referred
pain, RMQ and NDI were one, two, two and five, re-
spectively. In total, twenty-four patients (2.8%) failed to
respond to at least one of the questionnaires. Data on
medication were checked against invoicing data held at
the Ib-Salut, and data on prescription of surgery were
checked against hospital registries. Therefore, there were
no missing data for these variables.
Standards established in the contract on patients’ clin-
ical evolution, use of drugs and surgery, were met, both
at the yearly analysis (Tables 2, 3 and 4) and the monthly
analyses (data not shown). In the yearly analysis, the dif-
ference between median severity of local pain at baseline
and at discharge was 57.1%. Corresponding values for
referred pain, LBP-related disability and NP-related dis-
ability were 75.0%, 53.8.0% and 45.0% (Tables 2, 3 and
4). Patients taking medication for the reason they werereferred to NRT, were 751 upon referral, and 218
(29.0%) at discharge. Spinal surgery was not prescribed
to any of the patients who underwent NRT during 2011
(Tables 2, 3 and 4).
There were no discrepancies between providers, ana-
lysts and the administrative staff of the Ib-Salut. Given
these results, the Ib-Salut paid 100% of the amount in-
voiced for NRT interventions.Discussion
Shared risks contracts (SRCs) have taken center stage in
the regulatory framework related to the adoption of new
technologies, and numerous publications have described
them in depth, reporting many obstacles for their gener-
alisation into routine practice [63-70]. These obstacles
include: providers and the industry can perceive SRCs as
a threat to their income, which may stifle research and
innovation; payers may be unenthusiastic because of the
added burden in their administrative workload; in the
case of certain technologies, concerns may exist over the
balance between potential savings and monitoring costs;
follow-up of relevant outcomes through validated instru-
ments in routine practice may be difficult; and SRCs
may be used for implementing technologies which lack
evidence on effectiveness in specific geographic areas,
while patients are denied access to them in other
settings, leading to inequities across health areas within
a single Health Service [13-18,71,72].
NRT was selected for exploring the feasibility and
effectiveness of using risk sharing tools for quality control
and value-based reimbursement of a non-pharmacological
technology in Spain, because it complied with the following
three requisites: a) the efficacy, effectiveness and cost/effect-
iveness of the procedure had been assessed through high
quality RCTs and studies in clinical practice [32-35,40-43],
which made it feasible for the contract to establish
evidence-based, realistic standards, b) it had been
implemented in routine practice in the same applica-
tion conditions which were used in those studies, with
the same indication criteria and education and training
standards [32-35,40-43,58], c) post-adoption surveil-
lance mechanisms already existed and had shown to be
comprehensive and valid [40-42], which made it pos-
sible to use risk sharing tools at virtually no additional
cost. Generalising this approach to technologies which
do not comply with these pre-requisites may be diffi-
cult and require additional costs. However, results
from the current study show that it is indeed feasible
to use this approach for a non-pharmacological health
technology, and set a precedent for exploring the feasi-
bility of generalising this approach to other treatments
for NP, TP and LBP, and potentially treatments for
other conditions across the SNHS.
Table 1 Patient characteristics (n = 871)
Variables N Value
Gender (male) * 871 270 (31.0
Age (years) ¥ 871 56 (45; 67
Reason for referral to NRT * 871
Neck Pain (NP) 235 (26.9)
Thoracic pain (TP) 60 (6.9)
Low Back Pain (LBP) 576 (66.2)
Employment status *
Passive (students, housewife, etc.) 535 320 (59.8)
Receiving financial compensation
for LBP, TP or NP
34 (6.3)
Working 215 (40.2)
Duration of pain, since first
diagnosis (days) ¥
763 2,555 (730; 4,380)
Duration of pain since first diagnosis,
categorised *
763
≤ 1 year 136 (17.8)
1-5 years 219 (28.7)
5-10 years 204 (26.7)
>10 years 204 (26.7)
Duration of current pain episode (days) ¥ 809 180 (60; 365)
Duration of current pain episode (days),
categorised *
809
Subacute (≤ 90 days) 309 (38.2)
Chronic (>90 days) 500 (61.7)
Pregnancy * 2 (0.3)
Other comorbidities * 601 677 (84.4)
Involved in work-related claims * 802 14 (3.3)
Involved in litigation * 427 8 (1.9)
Baseline severity of local pain
(NP, TP or LBP) (VAS score) ¥
426 7.0 (6.0: 9.0)
870 660 (75.8)
Reporting referred pain at baseline* 871 6.0 (2.0; 8.0)
Baseline severity of referred
pain (VAS score) ¥♦
660 13 (9.0; 17.0)
Baseline lumbar disability (RMQ score) ¥♦ 574 40 (30.0; 50.0)
Baseline neck disability (NDI score) ¥♦ 229
Diagnostic procedures undergone
during the current pain episode,
before being referred for NRT*
69 (7.9)
X-Ray 871 98 (11.2)
MRI 871 21 (2.4)
Other¤ 871
Imaging findings * 698 (80.1)
Disc degeneration 871 137 (15.7)
Facet joint degeneration 871 68 (7.8)
Scoliosis 871 3 (0.3)
Difference in leg length 871 14 (1.6)
Spondylolisis 871 50 (5.7)
Table 1 Patient characteristics (n = 871) (Continued)
Spondylolisthesis 871 87 (9.9)
Spinal stenosis 871 229 (26.3)
Disc protrusion 871 340 (39.0)
Disc herniation (extrusion) 871 419 (48.1)









Other opioids 568 (65.2)
NSAIDs 25 (2.8)
Steroids 132 (15.1)
Muscle relaxants 164 (18.8)
Otherɣ
Non pharmacological treatments* 871 42 (4.9)
Physical therapy/Rehabilitation 7 (0.8)
Had undergone surgery for the current
episode, before being referred for NRT*
NP: Neck Pain TP: Thoracic pain LBP: Low back pain.
VAS: Visual Analogue Scale (range from better to worse; 0–10).
RMQ: Roland-Morris Questionnaire (range from better to worse: 0–24).
NDI: Neck Disability Index (range from better to worse: 0–100).
NRT: Neuro-reflexotherapy intervention.
*Frequency (%); ¥ Median (P25; P75);
¤Other diagnostic procedures: EMG, CT scan, scintigraphy.
∞Other imaging findings: annular tear, loss of cervical lordosis, loss of thoracic
cifosis, loss of lumbar lordosis, horizontalization of the sacrum, lumbarization
of S1, sacralization of L5.
♦ In patients in whom the variables “referred pain”, “RMQ” and “NDI” were
applicable (660 patients who reported having referred pain, 235 who were
referred for neck pain and 576 who were referred for low back
pain, respectively).
ɣ Other drugs: anti-epileptics or antidepressants prescribed for treating pain.
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rehabilitation or surgical procedures [1,30], are not
supported by solid evidence on effectiveness and cost/ef-
fectiveness, but are nevertheless used in routine clinical
practice, both in Europe and the US, without any post-
adoption surveillance mechanisms. Applying the ap-
proach described in this study to these technologies may
prove challenging, but may also lead to larger savings
and potentially better outcomes and reduced risks for
patients. In fact, available data suggest that, for instance,
the use and cost of spinal fusion for common low back
pain are soaring, without any evidence that this increase
is associated with an improvement in clinical outcome
[26,73]. Implementing post-marketing surveillance mecha-
nisms for each of these technologies separately may be
more efficient in the case of the most expensive technolo-
gies, such as spinal fusion [26], than in the case of low-cost
Table 2 Results on clinical outcomes (N=871)
Clinical outcome¥ N¤ Baseline score Score at discharge Improvement
Local pain (NP, TP or LBP) (VAS) 870 7 (6–9) 3 (1–5) 57.1%
Referred pain (VAS) ♦ 657 6 (2–8) 1.5 (0–4) 75.0%
LBP-related disablity (RMQ) ♦ 573 13 (9–17) 6 (2–12) 53.8%
NP-related disability (NDI) ♦ 219 40 (30–50) 22 (15–34) 45.0%
NP: Neck pain; TP: Thoracic pain; LBP: Low back pain.
¥ Median (P25; P75).
¤ Number of patients who answered the questionnaires at baseline and when discharged.
♦ In patients in whom the variables “referred pain”, “RMQ” and “NDI” were applicable (660 patients who reported having referred pain, 576 who were referred for
low back pain, and 235 who were referred for neck pain, respectively).
VAS: Visual Analogue Scale (range from better to worse: 0–10).
RMQ: Roland-Morris Questionnaire (range from better to worse: 0–24).
NDI: Neck Disability Index (range from better to worse: 0–100).
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efficient strategy might be to establish a prospective registry
for patients with NP, TP and LBP, gathering data on all pro-
cedures relative to their condition. In fact, one of the top
priorities recommended by the Institute of Medicine for
investing the $1.1 billion devoted to comparative effective-
ness research by the 2009 American Recovery and Re-
investment Act, was to “establish a prospective registry to
compare the effectiveness of treatment strategies for low
back pain without neurological deficit or spinal deformity”
[74]. A pilot test in 17 primary care and specialty centres,
shows that it is feasible to implement a valid registry for
these patients within the SNHS [75]. Generalising this
registry might facilitate the use of risk sharing tools for
quality control and value-based reimbursement.
The follow-up period in this study was 3 months,
which may be seen as relatively short. However, NRT fo-
cuses on treating the current pain episode, not on
preventing relapses, and this period appears to be clinic-
ally relevant and appropriate for this purpose. In fact,
the prognosis of chronic low back pain is determined by
changes in pain and disability occurring in the initial
period [76]. Moreover, previous studies have shown that
NRT can be repeated if relapses occur, although the pro-
portion of subjects who suffer from relapse after NRT
within three years, is below 10% [41]. In addition, three
months is the clinical follow-up period which has been







Proportion of patients using
medication at discharge
Any type 751 218 29.0%
NSAIDs 568 125 22.0%




Other drugsɣ 145 32 11.9%
* Includes opioids and non-opioids.
ɣ Other drugs: anti-epileptics or antidepressants prescribed for treating pain.therefore, the follow-up period for which data on results
to be expected were available when this study was devel-
oped [40-43]. Finally, studies with NP and LBP patients
conducted in routine practice within the Spanish Na-
tional Health Service have shown that losses to follow-
up are minimal up to 3 months [34,43,60,61,77,78], but
start to rise at 6 months [61,77-79], and are substantial
thereafter [34,78]. For these reasons, a 3-month follow-
up period was deemed appropriate when designing this
study.
Validity of data determining whether standards
established in the agreement have been met (Tables
2, 3 and 4) should be discussed. Patients’ clinical
evolution was assessed through previously validated
methods [44,48,59], and are consistent with data
from previous RCTs and studies in clinical practice
[32-35,40-43]. Data on use of medication and rates of
spinal surgery was shown to be accurate after having
been checked against the Ib-salut activity and phar-
macy registries. The later include data on all drugs pre-
scribed as well as those dispensed and invoiced by
pharmacies. Moreover, standards on use of medication
and surgery rates which were agreed upon, were calcu-
lated to ensure that funds invested by the Ib-Salut in
NRT were cost-effective.
High rates of excluded patients, losses to follow-up
and missing data, may introduce bias; in this study, less
than 5% of the patients who underwent NRT were ex-
cluded because adverse events required early extraction
of the surgical material, there were no losses to follow-
up, and missing data were below 3% (Tables 1, 2, 3 and
4). These features suggest that generalisability of these
results to LBP patients treated with NRT within the




Patients in whom surgery was prescribed
after having undergone NRT
%
871 0 0
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institution which specialises in NP, TP and LBP research
and, in fact, is responsible for most Spanish research in
this field [57]. The staff of the Ib-Salut in charge of post-
adoption surveillance for NRT, members of the team
analysing results, researchers involved in this study, and
clinicians performing NRT are paid a fixed salary and
have no economic incentives for applying the procedure
in cases in which it is not indicated, or for biasing ana-
lysis of results. The use of post-adoption surveillance
and shared risk tools in routine practice may be more
difficult when for-profit providers are involved, in set-
tings where these conditions are not met, or in which
clinicians are paid on a fee-for-service basis [13-15].
Nevertheless, the potential of savings may be larger in
these settings.
Randomised controlled trials (RCTs) are the gold
standard for assessing the efficacy, effectiveness and
cost/effectiveness of any health technology. In an ideal
world, all health technologies would be assessed through
high quality RCTs before being used in the clinical envir-
onment, and post-adoption surveillance methods would
be applied from the start of their use in routine practice.
However, strong incentives against this approach exist
and, as many examples show, many technologies are
implemented in routine practice in the absence of such
an evidence, or even disregarding the evidence against
implementation [2,3,80]. No form of post-adoption sur-
veillance can substitute the evidence deriving from
RCTs, but using post adoption surveillance combined
with risk sharking tools for all technologies that lack
long term effectiveness and safety data and for which
costs of usage are higher than monitoring costs, is likely
to improve the efficiency of health resources.
This approach is especially needed for technologies
which lack the support of robust evidence on efficacy,
effectiveness. In the field of NP and LBP this includes,
for instance, ultrasound for LBP, most forms of conser-
vative treatment for lumbar spinal stenosis or spinal
fusion for common LBP [26,30,53,73,81,82]. Moreover,
even in the case of technologies for which there is
evidence on effectiveness or cost/effectiveness, this ap-
proach would pave the way to comparative effective-
ness research and would likely contribute to reducing
inappropriate use (including off-label use, inappro-
priate referral, over-prescription of drugs and slim cli-
nical outcomes in some subgroups of patients), since it
would financially penalize any worsening in outcomes.
Examples within the same field in which this approach
would be suitable, include the inappropriate use of
magnetic resonance imaging, or the prescription of
spinal surgery in cases other than symptomatic disc
herniation or spinal stenosis complying with surgical
criteria [51-53,55,56,83,84].The absence of guidelines regarding the use of SRC
and the expected increase in its use in the near future in
Spain, calls for regulatory action. Some preliminary work
has been done in this direction [85].
Conclusions
Results from this experience show that it is feasible an
effective to combine post adoption surveillance methods
with risk sharing tools for controlling quality of care and
support value-based reimbursement decisions for NRT.
The feasibility of generalizing this approach to other
settings and to other non-pharmacological treatments
should be explored, since this is likely to improve the
efficiency of health resources.
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